| Prospective identification of tumorigenic breast cancer cells M Al-Hajj, MS Wicha, A Benito-Hernandez, SJ Morrison, MF Clarke Proceedings of the National Academy of Sciences 100 (7), 3983-3988, 2003 | 13913 | 2003 |
| Self-renewal and solid tumor stem cells M Al-Hajj, MF Clarke Oncogene 23 (43), 7274-7282, 2004 | 1395 | 2004 |
| Stem cells in normal breast development and breast cancer G Dontu, M Al‐Hajj, WM Abdallah, MF Clarke, MS Wicha Cell proliferation 36, 59-72, 2003 | 882 | 2003 |
| Therapeutic implications of cancer stem cells M Al-Hajj, MW Becker, M Wicha, I Weissman, MF Clarke Current opinion in genetics & development 14 (1), 43-47, 2004 | 795 | 2004 |
| CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial S Cordoba, S Onuoha, S Thomas, DS Pignataro, R Hough, S Ghorashian, ... Nature medicine 27 (10), 1797-1805, 2021 | 223 | 2021 |
| Cancer stem cells and oncology therapeutics M Al-Hajj Current opinion in oncology 19 (1), 61-64, 2007 | 194 | 2007 |
| Isolation and use of solid tumor stem cells MF Clarke, SJ Morrison, MS Wicha, M Al-Hajj US Patent 6,984,522, 2006 | 190 | 2006 |
| In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling EB Al-Hajj Muhammad Cancer Cell 24 (1), 45-58, 2013 | 183 | 2013 |
| Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma K Straathof, B Flutter, R Wallace, N Jain, T Loka, S Depani, G Wright, ... Science translational medicine 12 (571), eabd6169, 2020 | 171 | 2020 |
| ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome AM Elliott, MA Al-Hajj Molecular Cancer Research 7 (1), 79-87, 2009 | 146 | 2009 |
| Isolation and use of solid tumor stem cells MF Clarke, SJ Morrison, MS Wicha, M Al-Hajj US Patent 7,115,360, 2006 | 116* | 2006 |
| Prospective identification and characterization of breast cancer stem cells M Clarke, M Wicha, M Al-Hajj US Patent App. 10/497,791, 2005 | 61 | 2005 |
| Compositions and methods for characterizing, regulating, diagnosing, and treating cancer M Clarke, M Al-Hajj US Patent App. 11/050,282, 2005 | 59 | 2005 |
| Method for treating cancer using a notch4 ligand antagonist MF Clarke, MS Wicha, M Al-Hajj US Patent 7,754,206, 2010 | 57 | 2010 |
| Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed/refractory multiple myeloma (RRMM) R Popat, S Zweegman, J Cavet, K Yong, L Lee, J Faulkner, ... Blood 134, 3112, 2019 | 51 | 2019 |
| The ABCs of cancer stem cell drug resistance. A Elliott, J Adams, M Al-Hajj IDrugs: the investigational drugs journal 13 (9), 632-635, 2010 | 51 | 2010 |
| Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed/refractory B-cell acute … PJ Amrolia, R Wynn, RE Hough, A Vora, D Bonney, P Veys, R Chiesa, ... Blood 134, 2620, 2019 | 47 | 2019 |
| Prospective identification and characterization of breast cancer stem cells MF Clarke, MS Wicha, M Al-Hajj US Patent App. 11/651,214, 2009 | 46 | 2009 |
| Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL. W Osborne, M Marzolini, E Tholouli, A Ramakrishnan, CR Bachier, ... Journal of Clinical Oncology 38 (15_suppl), 8001-8001, 2020 | 45 | 2020 |
| Simultaneous targeting of CD19 and CD22: phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy, in pediatric patients with relapsed/refractory B … PJ Amrolia, R Wynn, R Hough, A Vora, D Bonney, P Veys, K Rao, ... Blood 132, 279, 2018 | 45 | 2018 |